International Journal of Diabetes Mellitus
Volume 1, Issue 1 , Pages 2-6 , April 2009

Adding rosiglitazone to metformin in patients with type 2 diabetes: Effect on diabetes control and metabolic parameters

  • Hussein Raef

      Affiliations

    • Department of Medicine (MBC-46), King Faisal Specialist Hospital and Research Center (KFSH & RC), P.O. Box 3354, Riyadh 11211, Saudi Arabia
    • Corresponding Author InformationCorresponding author. Tel.: +966 1 442 7490; fax: +966 1 442 4771.
    • ,
  • Abdulraof Al-Mahfouz

      Affiliations

    • Department of Medicine (MBC-46), King Faisal Specialist Hospital and Research Center (KFSH & RC), P.O. Box 3354, Riyadh 11211, Saudi Arabia
    • ,
  • Abdullah Al-Khonaizan

      Affiliations

    • Department of Family Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

References 

  1. UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood glucose control with Metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  2. UK Prospective Diabetes Study Group (UKPDS 16) . Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–1258
  3. Turner RC, Cull CA, Frighi V, et al. for the (UKPDS) group. Glycemic control with diet, sulfonylurea, Metformin, or insulin in patients with type 2 DM: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005–12.
  4. Gerich JE. Matching treatment to pathophysiology in type 2 Diabetes. Clin Therapeut. 2001;23(5):646–659
  5. Matthews DR, Bakst A, Weston WM, et al. Rosiglitazone decreases insulin resistance and improves B cell function in patients with type 2 DM. Eur Assoc Study Diab. 1999;858:37
  6. Gastaldelli A, Miyazaki Y, Pettiti M, et al. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. JCEM. 2006;91(3):806–812
  7. McEvoy GK, editor, Rosiglitazone Maleate, AHFS drug information. American Society of Health System Pharmacists, Bethesda, Md; 2000. p. 2876–77.
  8. Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (over 60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diab Obes Metab. 2006;8(1):49–57
  9. Inzucchi Silvio E, Maggs David G, Spollett Geralyn R, et al. Efficacy and metabolic effects of Metformin and troglitazone in type II diabetes mellitus. NEJM. 1998;338:867–872
  10. Fonesca V, Rosenstock J, Patwardhan R, et al. Effect of Metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695–1702
  11. Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa J, et al. Efficacy and safety of rosiglitazone plus Metformin in Mexicans with type 2diabetes. Diab Metab Res Rev. 2002;18:127–134
  12. Haffner S, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–684
  13. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In MacroVascular Events): a randomized controlled trial. Lancet 2005;366(9493):1279–89.
  14. Rennings AJ, Smits P, Stewart MW, et al. Fluid retention and vascular effects of rosiglitazone in obese, insulin resistant, nondiabetic subjects. Diab Care. 2006;29(3):581–587
  15. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of Metformin compared with dose escalation of Metformin in type 2 diabetes: the EMPIRE study. Curr Med Res Opin. 2005;21(12):2029–2035
  16. Samaha FE, Szapary PO, Iqbal N, et al. Effects of Rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26(3):624–630
  17. Derosa G, Cicero AF, Dangelo A, et al. Thiozolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res. 2005;28(11):917–924
  18. Qayyum R, Adomaityte J. A meta-analysis of the effect of Thiozolidinediones on blood pressure. J Clin Hypertens (Greenwich). 2006;8(1):19–28
  19. Kahn SE, Haffner SM, Heise MA, et al. for the ADOPT Study Group. Glycemic durability of Rosiglitazone, Metformin, or Glyburide monotherapy. N Engl J Med 2006;355(23):2427–43.
  20. The DREAM trial investigators. Effect of Rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006;368:1096.
  21. Davidson MB. Clinical implications of the DREAM study. Diab Care. 2007;30:418
  22. Niessen SE, Wolski MPH. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457
  23. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med. 2007;357:28
  24. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 2007;357:67
  25. Schwartz AV, Sellmeyer DE, Vittinghoff E. Thiazolidinedione use and bone loss in older diabetic adults. JCEM. 2006;91(9):3349
  26. Pendsay SP, Dhanvijay VP, Joshi PP. Efficacy of rosiglitazone with glibenclamide and metformin combination in type 2 diabetes. Int J Diab Develop Countries. 2002;22(2):61–69
  27. Panikar V, Chandalia HB, Joshi S, et al. Beneficial effects of triple drug combination of rosiglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy. Int J Diab Develop Countries. 2002;22(2):85–88
  28. Kang HW, Kim DJ, Lee MS, et al. Pathophysiologic heterogeneity in the development of type 2 diabetes mellitus in Korean subjects. Diab Res Clin Pract. 2005;69(2):180–187
  29. Mistui R, Fukushima M, Nishi Y, et al. Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. Metabolism. 2006;55(1):53–58
  30. Raptis SA, Dimitriadis GD. Oral hypoglycaemic agents: insulin secretagogues, alpha glucosidase inhibitors and insulin sensitizers. Endocrinol Diab. 2001;109(suppl. 2):S265–S287
  31. Home PD, Jones NP, Pocock SJ, et al. The (RECORD) study. Diab Med. 2007;24(6):626–634

PII: S1877-5934(09)00002-2

doi: 10.1016/j.ijdm.2009.03.001

International Journal of Diabetes Mellitus
Volume 1, Issue 1 , Pages 2-6 , April 2009

Article Tools

* Image Usage & Resolution